HEMAB THERAPEUTICS HOLDINGS
COAGNASDAQTrading Snapshot
- Day Range
- $38.75 – $42.23
- 52-Week Range
- $23.00 – $55.42
- Volume (shares)
- 1,195,908
- Avg Volume (shares)
- —
- Shares Outstanding
- 46.7M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -29.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.56
- Dividend Yield
- 0.00%
HEMAB THERAPEUTICS HOLDINGS
COAGFinancial history unavailable.
StockOtter · stockotter.spaceAbout HEMAB THERAPEUTICS HOLDINGS
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Hemab Therapeutics (NASDAQ:COAG) Shares Gap Down – Here’s What Happened
Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG - Get Free Report) gapped down prior to trading on Thursday. The stock had previously closed at $32.60, but opened at $30.82. Hemab Therapeutics shares last trade
Hemab Therapeutics (NASDAQ:COAG) Sees Strong Trading Volume – Should You Buy?
Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG - Get Free Report) saw strong trading volume on Wednesday. 332,235 shares were traded during trading, a decline of 11% from the previous session's volume of 372,680 shares.
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Consensus Rating of “Moderate Buy” from Analysts
Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the firm, Marketbeat reports. One research anal
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board Keli Walbert brings two decades of commercial leadership and proven track record of successful launches
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care from a healthcare pro